作者: Andrea Schilling , Mercedes Macias Parra , Maricruz Gutierrez , Jaime Restrepo , Santiago Ucros
关键词:
摘要: BACKGROUND: This study in 11- to 15-year-old boys and girls compared the immunogenicity safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] vaccine) administered either concomitantly or nonconcomitantly with 2 vaccines routinely this age group (Menactra [MCV4; Neisseria meningitidis serotypes A/C/Y/W-135] Adacel [Tdap; diphtheria/tetanus/acellular pertussis]). METHODS: Participants received 9vHPV vaccine at day 1 months 6; concomitant ( n = 621) MCV4/Tdap 1; nonconcomitant 620) month 1. Antibodies HPV-, MCV4-, Tdap-relevant antigens were determined. Injection-site systemic adverse events (AEs) monitored for 15 days after any vaccination; serious AEs throughout study. RESULTS: The geometric mean titers all HPV types 4 weeks dose 3, proportion subjects a fourfold rise greater N injection MCV4, antibody diphtheria tetanus ≥0.1 IU/mL, pertussis Tdap noninferior group. swelling occurred more frequently There no vaccine-related AEs. CONCLUSIONS: Concomitant administration was generally well tolerated did not interfere response these vaccines. strategy would minimize number visits required deliver each individually.